BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

660 related articles for article (PubMed ID: 25875699)

  • 1. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
    Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
    J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety.
    Cicalese MP; Ferrua F; Castagnaro L; Rolfe K; De Boever E; Reinhardt RR; Appleby J; Roncarolo MG; Aiuti A
    Mol Ther; 2018 Mar; 26(3):917-931. PubMed ID: 29433935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ADA Deficiency: Evaluation of the Clinical and Laboratory Features and the Outcome.
    Cagdas D; Gur Cetinkaya P; Karaatmaca B; Esenboga S; Tan C; Yılmaz T; Gümüş E; Barış S; Kuşkonmaz B; Ozgur TT; Bali P; Santisteban I; Orhan D; Yüce A; Cetinkaya D; Boztug K; Hershfield M; Sanal O; Tezcan İ
    J Clin Immunol; 2018 May; 38(4):484-493. PubMed ID: 29744787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency.
    Shaw KL; Garabedian E; Mishra S; Barman P; Davila A; Carbonaro D; Shupien S; Silvin C; Geiger S; Nowicki B; Smogorzewska EM; Brown B; Wang X; de Oliveira S; Choi Y; Ikeda A; Terrazas D; Fu PY; Yu A; Fernandez BC; Cooper AR; Engel B; Podsakoff G; Balamurugan A; Anderson S; Muul L; Jagadeesh GJ; Kapoor N; Tse J; Moore TB; Purdy K; Rishi R; Mohan K; Skoda-Smith S; Buchbinder D; Abraham RS; Scharenberg A; Yang OO; Cornetta K; Gjertson D; Hershfield M; Sokolic R; Candotti F; Kohn DB
    J Clin Invest; 2017 May; 127(5):1689-1699. PubMed ID: 28346229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
    Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
    Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.
    Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Zhang F; Adams S; Bjorkegren E; Bayford J; Brown L; Davies EG; Veys P; Fairbanks L; Bordon V; Petropoulou T; Kinnon C; Thrasher AJ
    Sci Transl Med; 2011 Aug; 3(97):97ra80. PubMed ID: 21865538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.
    Cicalese MP; Ferrua F; Castagnaro L; Pajno R; Barzaghi F; Giannelli S; Dionisio F; Brigida I; Bonopane M; Casiraghi M; Tabucchi A; Carlucci F; Grunebaum E; Adeli M; Bredius RG; Puck JM; Stepensky P; Tezcan I; Rolfe K; De Boever E; Reinhardt RR; Appleby J; Ciceri F; Roncarolo MG; Aiuti A
    Blood; 2016 Jul; 128(1):45-54. PubMed ID: 27129325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients.
    Cooper AR; Lill GR; Shaw K; Carbonaro-Sarracino DA; Davila A; Sokolic R; Candotti F; Pellegrini M; Kohn DB
    Blood; 2017 May; 129(19):2624-2635. PubMed ID: 28351939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.
    Carbonaro DA; Zhang L; Jin X; Montiel-Equihua C; Geiger S; Carmo M; Cooper A; Fairbanks L; Kaufman ML; Sebire NJ; Hollis RP; Blundell MP; Senadheera S; Fu PY; Sahaghian A; Chan RY; Wang X; Cornetta K; Thrasher AJ; Kohn DB; Gaspar HB
    Mol Ther; 2014 Mar; 22(3):607-622. PubMed ID: 24256635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
    Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
    Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency.
    Reinhardt B; Habib O; Shaw KL; Garabedian E; Carbonaro-Sarracino DA; Terrazas D; Fernandez BC; De Oliveira S; Moore TB; Ikeda AK; Engel BC; Podsakoff GM; Hollis RP; Fernandes A; Jackson C; Shupien S; Mishra S; Davila A; Mottahedeh J; Vitomirov A; Meng W; Rosenfeld AM; Roche AM; Hokama P; Reddy S; Everett J; Wang X; Luning Prak ET; Cornetta K; Hershfield MS; Sokolic R; De Ravin SS; Malech HL; Bushman FD; Candotti F; Kohn DB
    Blood; 2021 Oct; 138(15):1304-1316. PubMed ID: 33974038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency.
    Ferrua F; Brigida I; Aiuti A
    Curr Opin Allergy Clin Immunol; 2010 Dec; 10(6):551-6. PubMed ID: 20966749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
    Aiuti A; Cattaneo F; Galimberti S; Benninghoff U; Cassani B; Callegaro L; Scaramuzza S; Andolfi G; Mirolo M; Brigida I; Tabucchi A; Carlucci F; Eibl M; Aker M; Slavin S; Al-Mousa H; Al Ghonaium A; Ferster A; Duppenthaler A; Notarangelo L; Wintergerst U; Buckley RH; Bregni M; Marktel S; Valsecchi MG; Rossi P; Ciceri F; Miniero R; Bordignon C; Roncarolo MG
    N Engl J Med; 2009 Jan; 360(5):447-58. PubMed ID: 19179314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy/bone marrow transplantation in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreduction.
    Carbonaro DA; Jin X; Wang X; Yu XJ; Rozengurt N; Kaufman ML; Wang X; Gjertson D; Zhou Y; Blackburn MR; Kohn DB
    Blood; 2012 Nov; 120(18):3677-87. PubMed ID: 22833548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans.
    Candotti F; Shaw KL; Muul L; Carbonaro D; Sokolic R; Choi C; Schurman SH; Garabedian E; Kesserwan C; Jagadeesh GJ; Fu PY; Gschweng E; Cooper A; Tisdale JF; Weinberg KI; Crooks GM; Kapoor N; Shah A; Abdel-Azim H; Yu XJ; Smogorzewska M; Wayne AS; Rosenblatt HM; Davis CM; Hanson C; Rishi RG; Wang X; Gjertson D; Yang OO; Balamurugan A; Bauer G; Ireland JA; Engel BC; Podsakoff GM; Hershfield MS; Blaese RM; Parkman R; Kohn DB
    Blood; 2012 Nov; 120(18):3635-46. PubMed ID: 22968453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
    Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
    Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
    Smogorzewska EM; Weinberg KI; Kohn DB
    Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency.
    Silver JN; Elder M; Conlon T; Cruz P; Wright AJ; Srivastava A; Flotte TR
    Hum Gene Ther; 2011 Aug; 22(8):935-49. PubMed ID: 21142972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID.
    Sauer AV; Brigida I; Carriglio N; Hernandez RJ; Scaramuzza S; Clavenna D; Sanvito F; Poliani PL; Gagliani N; Carlucci F; Tabucchi A; Roncarolo MG; Traggiai E; Villa A; Aiuti A
    Blood; 2012 Feb; 119(6):1428-39. PubMed ID: 22184407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How We Manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID).
    Kohn DB; Gaspar HB
    J Clin Immunol; 2017 May; 37(4):351-356. PubMed ID: 28194615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.